SIM-0237

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameSIM-0237
Drug Alias NameSIM-0237SIM-237
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-IL15Anti-Programmed death-ligand 1
TargetsProgrammed death-ligand 1Interleukin-15
Therapy Area/IndicationsSolid tumoursUrinary Bladder Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSimcere Pharmaceutical Group Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Xiansheng Zaiming Pharmaceutical Biotechnology Co LtdSimcere Pharmaceutical Group LtdJiangsu Simcere Pharmaceutical Co Ltd
Inactive CompaniesHainan Xiansheng Re Ming Pharmaceutical Co Ltd
Active IndicationsSolid tumoursUrinary Bladder Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A